In the well-designed 2-year prospective study Kirkham and colleagues (2006) showed that in RA associated joints’ destruction, IL-17 effects were best seen in patients with shorter disease duration, and IL-1β effects were best pronounced in patients with longer disease duration. This evidence concerns the gene IL17A and rheumatoid arthritis.